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background:  An estimated 25% of patients with heart failure (HF) have atrial fibrillation (AF). Despite the high prevalence, this group 
remains understudied. This study looks at sex differences in discharge medications for patients with HF complicated by AF.
Methods:  The GWTG-HF study enrolled 6,496 HF patients that presented to the Cooper Health System from 2005 - 2012. 21.26% of 
these patients had AF. Patient characteristics and discharge medications were compared by sex.
results:  Women presenting with HF complicated by AF were older (p<0.001) and had a higher CHA2DS2-VASc score (3.7 ± 1.8 vs. 2.4 ± 
1.9, p<0.001). On admission, women had a higher ejection fraction (p<0.001), higher total cholesterol (p=0.018), and higher systolic blood 
pressure (p<0.001). On average women were prescribed fewer discharge medications than men (p=0.002). Women were less likely to be 
prescribed an ACE Inhibitor (p=0.002), aldosterone antagonist (p=0.008), isosorbide (p<0.001), a lipid-lowering agent (p=0.005), and an 
anticoagulant (p=0.002) (Table).
Conclusion:  Sex differences exist for discharge medications in patients with HF complicated by AF. Although some of these differences 
in therapy might be explained by the higher prevalence of diastolic HF in women, under-treatment related to anticoagulation is surprising, 
particularly since women have a higher CHAD2DS2-VASc score, suggesting a higher risk of thromboembolic complications. Further 
research is needed to understand these differences in treatment.
Patient Discharge Medications and Treatments by Sex
Women
(n=591)
%
Men
(n=790)
%
P value
Medications prescribed at discharge
ACE inhibitor
Aldosterone antagonist
Angiotensin II Receptor Blocker
Antiarrhythmic
Anticoagulant (i.e. Warfarin, Pradaxa)
Antiplatelet agent (excluding aspirin)
Aspirin
Beta blocker
Clopidogrel
Diabetes management therapy
Isosorbide
Lipid lowering agent
45.9
14.7
13.0
15.2
52.6
0.68
59.7
78.2
15.7
28.6
8.0
57.5
54.3
20.3
10.0
13.7
61.0
0.38
61.5
81.1
16.0
30.6
13.5
65.0
0.002
0.008
0.079
0.414
0.002
0.442
0.500
0.174
0.914
0.348
0.001
0.005
